HC Wainwright Analysts Decrease Earnings Estimates for BOLT

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) – Stock analysts at HC Wainwright lowered their FY2024 earnings per share estimates for shares of Bolt Biotherapeutics in a research note issued to investors on Wednesday, November 13th. HC Wainwright analyst E. White now forecasts that the company will post earnings of ($1.57) per share for the year, down from their prior forecast of ($1.55). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Bolt Biotherapeutics’ current full-year earnings is ($1.52) per share. HC Wainwright also issued estimates for Bolt Biotherapeutics’ Q4 2024 earnings at ($0.34) EPS, FY2025 earnings at ($0.94) EPS and FY2026 earnings at ($0.74) EPS.

Bolt Biotherapeutics Stock Down 9.1 %

Shares of NASDAQ BOLT opened at $0.57 on Friday. The firm has a fifty day simple moving average of $0.64 and a two-hundred day simple moving average of $0.73. Bolt Biotherapeutics has a 12 month low of $0.55 and a 12 month high of $1.56. The company has a current ratio of 3.16, a quick ratio of 4.28 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $21.64 million, a PE ratio of -0.33 and a beta of 0.92.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its earnings results on Tuesday, November 12th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.04). The business had revenue of $1.14 million for the quarter, compared to the consensus estimate of $1.02 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%.

Hedge Funds Weigh In On Bolt Biotherapeutics

Institutional investors have recently bought and sold shares of the stock. FMR LLC boosted its position in Bolt Biotherapeutics by 33.2% during the 3rd quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after acquiring an additional 28,773 shares in the last quarter. Assenagon Asset Management S.A. bought a new stake in shares of Bolt Biotherapeutics during the second quarter valued at approximately $26,000. Finally, Acuitas Investments LLC boosted its position in shares of Bolt Biotherapeutics by 21.7% during the second quarter. Acuitas Investments LLC now owns 630,507 shares of the company’s stock valued at $473,000 after purchasing an additional 112,555 shares in the last quarter. 86.70% of the stock is owned by institutional investors.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.